Test Overview
All coding exons (plus 15 bp upstream and downstream of each coding exon) of the targeted gene(s) are captured, sequenced using NGS and aligned to the human reference genome. A minimum NGS coverage of 20X is achieved for all coding exons +/- 5 bp, and a minimum coverage of 10X an additional 10 bp from +/- 6 bp through +/- 15 bp. A minimum coverage of 10X is achieved for all clinically significant promoter regions. Regions which do not meet these coverage metrics are filled with targeted Sanger Sequencing. Variants in the targeted regions that are of potential clinical significance, based on the ACMG guidelines for interpretation of sequence variants (PMID: 25741868), will be reported. Copy number variation is assessed by coverage depth within the targeted regions compared to a normalized reference file. Copy number variants within the targeted regions that are of potential clinical significance will also be reported. In addition to NGS, Sanger sequencing is used to amplify and sequence CHEK2 and PMS2 to avoid known pseudogene regions. All reported variants of potential clinical significance not meeting the sequencing quality criteria will be confirmed by a different technology.
Use for the detection of germline pathogenic variants in patients at increased risk for breast and ovarian cancer. Gene list: ATM, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, PALB2, PTEN, TP53.
Interpretive report provided.
* Reference ranges may change over time. Please refer to the original patient report when evaluating results.
This assay will not detect intronic mutations or copy number variants outside the region sequenced in the ATM, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, PALB2, PTEN, TP53 genes or mutations in other genes associated with these diseases will not be identified.
Test Details
28 days
- HBOC Germline Panel, High-Moderate Risk
- ATM
- BRCA1
- BRCA2
- BRIP1
- CDH1
- CHEK2
- PALB2
- PTEN
- TP53
Specimen Requirements
Collect specimen in a lavender top tube. Send intact specimen within 24 hours if stored at room temperature or within 5 days if stored refrigerated. Include the patient's family history, pedigree, and ethnicity on the test requisition. Obtaining informed consent from the patient prior to genetic testing is strongly recommended. If desired, a UMHS Request and Consent for Genetic Testing form can be obtained from the MMGL Molecular Genetics Laboratory by contacting the MLabs Client Services Center at 800-862-7284 or online at https://mlabs.umich.edu/media/188.
Additional Information
Insurance prior authorization may be needed for this genetic test. Please inquire with the patient's insurance company to determine if a prior authorization is necessary for payment. By ordering this test the clinician acknowledges that informed consent has been obtained from the patient as required by applicable state or federal laws and the ordering clinician has authorization from the patient permitting MLabs to report the test results to the ordering clinician. Test includes medical geneticist interpretation of results billed as a separate additional charge. This test is not available without interpretation.